Product news

Share this article:

Astellas Pharma won FDA approval for their sNDA for the use of Mycamine (micafungin sodium) for injection in the treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses. Mycamine was approved in 2005 for the treatment of patients with esophageal candidiasis and is the only echinocandin approved for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation.

Alpharma announced the availability of the Flector patch (diclofenac epolamine topical patch) 1.3% in the US. The adhesive patch delivers medication directly to the site of pain, offering a safe and effective alternative to widely used nonsteroidal anti-inflammatory drugs that are taken orally. The targeted delivery of Flector patch through the skin results in minimal systemic absorption of diclofenac.

MiddleBrook Pharmaceuticals received FDA approval of its NDA for once-daily Moxatag tablets 775 mg (amoxicillin extended-release tablets) for the treatment of adults and pediatric patients 12 years and older with pharyngitis and/or tonsillitis secondary to Streptococcus pyogenes (commonly referred to as strep throat).

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.